Generium
Manufacturing · Russia · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Testovskaya St 10, Moscow, Moscow, 12311...Phone Number
+7 4959884794 ext. 7020Website
www.generium.ruRevenue
$6.6 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
3
1
1
1
1
About Generium
Generium Pharmaceuticals is a leader in the orphan drug segment of the Russian biotechnology industry, focusing on the research and development of medications for rare and life-threatening diseases. The company has a robust R&D park capable of developing drugs from molecule creation to industrial production, ensuring quality control throughout the product lifecycle. Generium collaborates with biotechnology companies and scientific institutions worldwide to advance its innovative therapies. Their product pipeline includes treatments for various conditions, including oncology, autoimmune diseases, and allergies.Explore more
Generium Org Chart
AP
Senior CRA
OP
Junior Manager, Quality Assurance, Generium
SS
Manager, Quality Assurance
EZ
Junior Manager, Quality Assurance
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Generium your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Generium has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Generium launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Generium recently announced quarterly report
Click to see if Generium had a recent Job posting/layoffs
Generium, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Generium is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Generium
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Generium has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Generium is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Generium is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Generium.
Generium Tech Stack
Generium News & Media
IONTAS Antibody Enters Clinical Trial for Use in the Treatment of B Cell Acute Lymphoblastic Leukemia
CAMBRIDGE, England & MOSCOW--(BUSINESS WIRE)--IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, has been informed that International Biotechnology Center (IBC) Generium, a leading Russian biopharmaceutical company, focused on developing and commercialising pharmaceutical products for the treatment of orphan diseases and cancer, has received approval from the Russian Health Authorities to initiate clinical trials with its CD3/CD19 bispecific antiboGenerium Launches First Biosimilar of Dornase Alfa; Becomes Sixth Approved Product Using Selexis SUREtechnology Platform
GENEVA & MOSCOW--(BUSINESS WIRE)--Selexis SA and Generium JSC today announced that a sixth Selexis SUREtechnology Platform™-generated biological product has been approved for marketing. The latest approved product, dornase alfa inhalation solution, is used together with antibiotics, bronchodilators, and steroids to control symptoms of cystic fibrosis. Generium is the first company in the world to develop and market a biosimilar of dornase alfa. According to the National Institutes of Health,Generium Launches First Biosimilar of Eculizumab; Becomes Fifth Marketed Product Using Selexis SUREtechnology Platform
GENEVA & MOSCOW--(BUSINESS WIRE)--Selexis SA and Generium JSC today announced that a fifth Selexis SUREtechnology Platform™-generated biological product has been approved for marketing. The latest approved product is a biosimilar monoclonal antibody, eculizumab, indicated for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Generium is the first company in the world to develop and market a biosimilar of eculizumab. Paroxysmal nocturnal
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Generium
Sign Up For FreeTo access detailed company insights
Generium Pharmaceuticals is a leader in the orphan drug segment of the Russian biotechnology industry, focusing on the research and development of medications for rare and life-threatening diseases. The company has a robust R&D park capable of developing drugs from molecule creation to industrial production, ensuring quality control throughout the... Read More
